Women issued safety warning over period tracker apps
Experts have warned that women using period tracker apps face "real and frightening privacy and safety risks."
Academics from the University of Cambridge have said that personal information within the app can be collected and "sold at scale."
A new report from the Minderoo Centre for Technology and Democracy at Cambridge stated that this poses risks and harms for users.
Researchers have said that menstrual data can provide insights into people's health and their reproductive choices.
The apps can collect information on exercise, diet, medication, sexual preferences, hormone levels, and contraception use.
The authors of the report added that this information can be a "gold mine" for consumer profiling.
Many women who download the apps do so when they are trying to get pregnant, which the authors point out leads to a dramatic shift in shopping behaviour.
'Data on who is pregnant, and who wants to be, has therefore emerged as some of the most sought-after information in digital advertising,' they said.
The point out how period tracking apps have rapidly risen in popularity, with global downloads of the three most popular apps surpassing 250 million.
'Cycle tracking apps (CTA) are a lucrative business because they provide the companies behind the apps with access to extremely valuable and fine-grained user data,' the experts wrote in their new report.
'CTA data is not only commercially valuable and shared with an inextricable net if third parties (thereby making intimate user information exploitable for targeted advertising), but it also poses severe security risks for users.'
They point out that in the wrong hands, the data collected by the apps could result in health insurance 'discrimination'; risks to job prospects or even domestic abuse.
The research team called for better governance of the 'femtech' industry, including improved data security of these apps and for them to introduce 'meaningful consent options'.
They also called for public health bodies to launch alternatives to commercial tracking apps.
'Menstrual cycle tracking apps are presented as empowering women and addressing the gender health gap,' said Dr Stefanie Felsberger, lead author of the report.
'Yet the business model behind their services rests on commercial use, selling user data and insights to third parties for profit.'
'There are real and frightening privacy and safety risks to women as a result of the commodification of the data collected by cycle tracking app companies.'
Professor Gina Neff, executive director of Cambridge's Minderoo Centre, added: 'The use of cycle tracking apps is at an all-time high.
'Women deserve better than to have their menstrual tracking data treated as consumer data, but there is a different possible future.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
AI and Home Dialysis: From Prediction to Personalization
VIENNA — 'We are going to change anemia treatment. We are going to change fistula control. The future is going to be AI (artificial intelligence),' declared Adrian C.M. Covic, MD, PhD, at the opening of a session dedicated to AI and home dialysis at 62nd European Renal Association (ERA) Congress 2025. Covic, vice-rector for scientific research at Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania, emphasized that dialysis has seen limited improvement in mortality over the past 30-40 years. 'We haven't changed much,' he said, 'but AI may be the game changer.' 'Home dialysis is a highly standardized process that generates a large volume of medical data,' he explained in his presentation. Different machine learning models are already used in a cycle of AI-based clinical decision support — a cycle from problem identification through algorithm development and validation to real-world deployment. These models can process data from up to half a million patients and uncover variables that clinicians might overlook. And AI, he reported, has outperformed traditional models like the Kidney Failure Risk Equation in predicting when dialysis should begin and in forecasting mortality. In a head-to-head study, only 2 of 10 experienced nephrologists outperformed an AI model in predicting survival at 30 and 90 days. And 'only one was better than AI at 1 year,' said Covic. Beyond survival, AI models are also accurately predicting major adverse cardiac event and gastrointestinal bleeding hospitalization risks with hemodialysis. Diagnostic capabilities are also improving, Covic added. He described how natural language processing applied to clinical notes identified symptoms with far greater sensitivity than International Classification of Diseases, 10th Revision, coding. In simulated clinical cases, the large language model-based AI system AMIE, which has been optimized for diagnostic dialogue, outperformed physicians in diagnostic accuracy. 'AMIE was far better than the doctors in picking the right symptoms,' he said. On the treatment side, AI models are helping clinicians anticipate intradialytic hypotension 15-75 minutes in advance, with an area under the receiver operating characteristic curve (AUC) of 0.89, and manage vascular access by classifying aneurysms and predicting stenosis. In one example, a model achieved 86% classification accuracy. Another AI-enabled device, the DeepVAQ system, used photoplethysmography data to detect stenosis with an AUC of 0.86. Covic also presented evidence that AI improved anemia control. A model trained on 170,000 clinical records achieved a mean absolute prediction error in hemoglobin concentration of 0.59 g/dL and led to improved hemoglobin levels during implementation. 'We are close, for the very first time, to a meta-analysis for anemia management in dialysis through AI,' he said. Even device integration is advancing, with AI-enabled tools like phonangiography and robotic tomographic ultrasound improving vascular assessments. You won't need a technician — the device itself will standardize the analysis, he said. Despite his optimism, Covic issued a strong caveat: AI models are increasingly opaque, and 'we are not going to learn the algorithms,' he said. 'This process is close to beliefs in divinity.' Expanding Access Through Policy Shifting the focus to access, Rajnish Mehrotra, MD, MS, argued for policy solutions that leverage home dialysis with peritoneal dialysis (PD) to close the global dialysis gap. 'Nearly 2 million people die with kidney failure every year because they have limited access to kidney replacement therapy care,' said Mehrotra, Belding H. Scribner Endowed Chair in and professor of medicine and head of the Division of Nephrology at the University of Washington School of Medicine, Seattle. PD is ideal for low-resource settings, he said. 'Hemodialysis is personnel-intensive. PD is personnel-efficient.' PD also has a markedly lower carbon footprint, less than a quarter that of in-center hemodialysis. 'It substantially reduces the transportation burden on patients,' he added. Mehrotra cited Thailand's 2008 PD-first mandate, which rapidly expanded access. 'People who previously would have died because they did not get dialysis lived,' he said. Even though the policy was later relaxed, PD rates in Thailand remain high. In the US, financial reform drove a doubling of PD use after 2011. Reimbursement parity and bundled payments neutralized the incentives that had favored hemodialysis. 'This public policy has safely grown the use of PD and has been a spectacular success,' said Mehrotra. Telemedicine in Daily Practice Finally, Sabrina Milan Manani, MD, Department of Nephrology, Dialysis and Transplant, San Bortolo Hospital, Vicenza, Italy, turned to practical innovations that bring AI into patients' homes. 'Home dialysis is a corner[stone] of patient-centered care in nephrology,' she said. Her team uses a hybrid model of home visits and telemonitoring for home dialysis. With cloud-connected cyclers, clinicians review overnight dialysis sessions each morning and make remote prescription changes. 'It's a two-way communication system,' she noted. Manani presented outcomes from her center: Patients with remote monitoring had fewer urgent visits and fewer hospitalizations for disease-specific events. 'We observed that the patients felt more confidence with the care team and with the treatment,' she said. She also described a real-world protocol for integrating telemedicine, with frequent reviews of new patients' data during the first 15 days of treatment, tapering to weekly reviews for stable patients. We only invite the patient to come to the hospital if there is a clinical problem, she added. However, she acknowledged that not all patients benefit equally. Older individuals may struggle with connectivity or tech literacy, and the evidence for complication reduction remains mixed. 'The significant results were about disease-specific hospitalization and technical failure, but the evidence was low or very low,' said Manani. Still, she sees future promise in wearable devices and AI-enhanced alerts. 'Flexibility and innovation are essential for promoting home therapies,' she concluded. 'Remote monitoring could integrate the traditional follow-up, allowing safe, high-quality care.' The Road Ahead Key challenges in the integration of AI into kidney care remain. As Covic put it, 'Prediction is currently the most widely used application of AI and machine learning in dialysis,' but rigorous studies are needed. 'We should now move to this sort of randomized control trials,' he urged. The issues of trust and interpretability loom large with AI. 'It is really difficult, or even impossible, to know how they produce results,' Covic said of AI models. But the results, increasingly, are hard to ignore. 'Optimized machine learning models could enhance risk identification and drive preemptive interventions,' he concluded. No funding or relevant financial relationships were declared.
Yahoo
an hour ago
- Yahoo
6 toilet habit changes you should always see a doctor about
No one enjoys talking about bowel movements. But ignoring the signs your body is trying to send you can mean putting off a diagnosis you really need to hear. Just ask TOWIE star Chloe Meadows. The reality TV regular recently shared on Dr Oscar Duke's Bedside Manners podcast that she'd spent a decade silently struggling with bleeding, stomach pain and extreme fatigue before finally getting a diagnosis: ulcerative colitis, a chronic condition that causes inflammation and ulcers in the colon. She lived with on-and-off symptoms for years, assuming they'd passed. It wasn't until age 26, when she became visibly unwell, that a blood test led her to A&E and finally, a diagnosis. Meadows' experience is an important reminder that when your toilet habits change – and stay changed – it's time to talk to your GP. Below, we break down six toilet-related red flags that experts say you should never ignore. And no, it's not just about your bowel movements; your wee, urgency levels, and even smells all matter, too. Whether you're suddenly constipated, dealing with constant diarrhoea, or noticing your stool looks different (narrower, paler or greasy), changes that last longer than a few weeks are worth investigating. The NHS advises that ongoing shifts in bowel habits could be linked to anything from diet and stress to Irritable Bowel Syndrome (IBS), coeliac disease or inflammatory bowel disease (IBD). In some cases, persistent symptoms could be a sign of bowel cancer, so don't brush them off. When to see your GP: If your usual routine has changed for more than two to three weeks, especially if it's paired with stomach pain, fatigue, or weight loss. It might be bright red or dark and tarry; either way, it's not something to ignore. Bright red blood can come from piles or small tears, but darker blood might mean there's bleeding higher up in the digestive system. When to see your GP: If you see blood in your poo. You may be offered a stool test, or in some cases, a referral for further checks. If anything feels amiss and suddenly starts to sting, burn or feel uncomfortable, you might assume it's a urinary tract infection (UTI). And often, that's true. But it can also be a sign of kidney stones or bladder issues. Blood in your urine should also be taken seriously, even if it only happens once. When to see your GP: If you have pain while urinating, see blood or feel the urge to go far more often than usual. Needing the loo more often than usual (especially at night), feeling like you can't wait, or leaking a little when you cough, sneeze or laugh could signal an overactive bladder, prostate issues (in men), or pelvic floor dysfunction. These symptoms might feel embarrassing, but they're generally common and manageable with the right support. When to see your GP: If bladder leaks or urgency interfere with your daily life, or if you notice a sudden change in how often you need to go. A little mucus in your stool isn't always a worry, but frequent slimy stools can be a sign of infection or inflammation in your gut. When to see your GP: If mucus appears regularly, especially if it comes with bloating, pain or a change in bowel movements. If going to the toilet has become uncomfortable, painful, or feels like hard work, that's your body waving a red flag. Regular straining can cause or worsen hemorrhoids, but it might also signal bowel issues or even neurological problems affecting your pelvic floor. When to see your GP: If you're straining often, feel like you're not fully emptying your bowels, or notice pain during or after a bowel movement. If you're unsure, remember that everyone has their own baseline of what's 'normal'. However, there are a few simple signs to watch for as a guide. According to the Bladder and Bowel Health Service, healthy bowel movements should be soft, smooth and easy to pass; ideally at least three times a week. You should also be able to urinate without pain or discomfort. If you also notice you're often bloated, tired, straining, or notice blood or mucus, it's time to speak to your GP. Changes might be harmless, but they're always worth checking. Read more on bowel habits: This Poop Chart Will Tell You If Your Bathroom Habits Are Actually Healthy Or If You Need To See A Doctor ASAP (Buzzfeed, 4-min read) How 'blowing bubbles' and 'mooing' can help ease constipation, according to NHS doctor (Yahoo Life UK, 4-min read) Bowel cancer cases in young people rising sharply in England, study finds (PA Media, 4-min read)
Yahoo
2 hours ago
- Yahoo
NHS waiting list for planned treatment falls to lowest level in two years
The NHS waiting list for planned hospital treatment has fallen to its lowest level for two years, figures show. An estimated 7.39 million treatments were waiting to be carried out at the end of April, relating to 6.23 million patients – down from 7.42 million treatments and 6.25 million patients at the end of March. These are the lowest figures since March 2023 for treatments and April 2023 for patients. The news comes after Chancellor Rachel Reeves gave the NHS a cash injection worth an extra £29 billion per year. Health and Social Care Secretary Wes Streeting said: 'We are putting the NHS on the road to recovery after years of soaring waiting times, by providing record investment and fundamental NHS reform. 'Thanks to our interventions and the hard work of NHS staff, the overall waiting list has now fallen in April for the first time in 17 years – dropping by almost a quarter of a million since we took office. 'This is just the start. We've delivered millions of extra appointments since July, we are pushing on with our mission to get the NHS working for patients once again as we deliver our Plan for Change.' Within the new NHS figures, the number of longer waits has grown. Some 1,361 patients in England had been waiting more than 18 months to start routine treatment at the end of April, up from 1,164 in March. There were 9,258 patients who had been waiting more than 65 weeks to start treatment, up from 7,381 the previous month. Overall, 190,068 people in England had been waiting more than 52 weeks to start routine hospital treatment, up from 180,242 at the end of March. The figure had previously fallen for 10 months in a row. NHS England said that, overall, the average time patients had been waiting for planned treatment fell to the lowest level since July 2022 – 13.3 weeks – despite services facing greater demand. Meghana Pandit, NHS England's co-national medical director, said NHS staff were working to 'turn the tide for patients waiting for care'. She said while huge pressure on services remains, 'we are starting to see a real difference across our services – this is just the start of the work we're doing to reform care and deliver improvements for patient'. The data also showed fewer people are getting a diagnosis of cancer or having it ruled out within four weeks. A total of 76.7% of patients urgently referred for suspected cancer were diagnosed or had cancer ruled out within 28 days in April, down from 78.9% in March and 80.2% in February. The Government and NHS England had set a target of March 2026 for this figure to reach 80%. The proportion of patients who had waited no longer than 62 days in April from an urgent suspected cancer referral, or consultant upgrade, to their first definitive treatment for cancer was 69.9%, down from 71.4% in March. GPs in England made 264,880 urgent cancer referrals in April, down from 272,165 in March but up year-on-year from 260,516 in April 2024.
